|
|
|
|
|
|
|
|
ScienceDaily
Successful ovarian cancer treatment often relies on catching it early. A study at The University of Texas MD Anderson Cancer Center may help point to a new method for women at risk.....
.....The study looked at antibodies produced by patients against the tumor gene TP53 which is mutated and overexpressed in the majority of ovarian cancers to see whether their presence would improve the ability of CA125 to detect ovarian cancer in an earlier stage.
"Anti-TP53 autoantibodies were detected an average of 13 months prior to rising CA125 levels and 33 months prior to diagnosis in patients who did not have a rising CA125," said Bast. "While only a quarter of cases are associated with anti-TP53 autoantibodies, when present, these antibodies promise to detect ovarian cancer at an earlier interval than CA125.". The data was presented on April 20 at the 2015 American Association for Cancer Research (AACR) Annual Meeting in Philadelphia.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.